Cone beam CT-based adaptive intensity modulated proton therapy assessment using automated planning for head-and-neck cancer

Table 1 Patient characteristics

Subsite	T stage	Treatment modality	Prescribed dose (Gy)	Number of fractions	Treatment intent	Fraction number when rCT is acquired
Nasopharynx	T1N1	IMPT	70, 59.5, 56	35	Definitive chemoradiation	17, 27
Parotid	T1N0	IMPT	60	30	Adjuvant radiation	10
Oral cavity	TxN3	VMAT	70, 63, 56	35	Re-irradiation	13
Oropharynx	T2N2	VMAT	70, 59.5, 56	35	Definitive chemoradiation	18
Oropharynx	T2N3	VMAT	70, 60, 56	35	Definitive chemoradiation	NA
Oropharynx	T1N2	VMAT	70, 59.5, 56	35	Definitive chemoradiation	NA
Oropharynx	T2N1	VMAT	70, 60, 56	35	Definitive chemoradiation	NA
Oropharynx	T2N3	VMAT	70, 60, 56	35	Definitive chemoradiation	NA
Oropharynx	T2N1	VMAT	70, 60, 56	35	Definitive chemoradiation	NA
Larynx	T4aN2c	VMAT	70, 63, 56	35	Definitive chemoradiation	NA
Hypopharynx	T1N3	IMPT	70, 63, 56	35	Definitive chemoradiation	2
Oropharynx	T3N1	VMAT	70, 59.5, 56	35	Definitive chemoradiation	NA
Larynx	T4aN2c	VMAT	70, 63, 56	35	Definitive chemoradiation	NA
Peripheral nerve	T1N0	IMPT	60	30	Adjuvant radiation	NA
Nasopharynx	T2N2	IMPT	70, 59.5, 56	35	Definitive chemoradiation	23
Parotid	T2N0	IMPT	60	30	Adjuvant radiation	22
Parotid	T2N0	IMPT	66	33	Adjuvant radiation	7, 12, 20
Oropharynx	TxN3	IMPT	66, 59.4, 56.1	33	Salvage chemoradiation	4
Nasopharynx	T4aN0	IMPT	66	33	Adjuvant chemoradiation	16
Oral cavity	T4aN0	IMPT	60	30	Salvage radiation	NA

ISSN: 1748-717X